Rasha Printz

Associate
Full contact info

I am motivated by my clients’ ingenuity and drive. Allow me to match your enthusiasm for innovation.

Passions

Hiking in the Shenandoah Valley

River Tubing

Reading Chuck Palahniuk

Perusing Medical News

Experience

Adaptive Phage Therapeutics Enters Into Definitive Merger Agreement With BiomX

March 6, 2024

Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.

Read more

Related contacts

Christian Plaza
Partner, Reston
Matthew D. Silverman
Special Counsel, San Diego
Brian Leaf
Partner, Reston
Matthew Schwee
Partner, Reston
Joyce Li
Associate, Chicago
Rasha Printz
Associate, Reston
John Lavoie
Partner in Charge – Reston, Reston
Kenneth Krisko
Partner, Reston
Eileen Marshall
Partner, Washington, DC
Phil Mitchell
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Rick Jantz
Associate, Los Angeles Santa Monica
Anne Luquette
Associate, San Francisco
Tyler McClure
Associate, San Francisco
Patricia Myers
Paralegal Specialist, Colorado
Douglas Lyles
Senior Research Services & Access Analyst

Halcyon Closes $44 Million Series A Financing Round

April 20, 2023

Cooley advised adaptive security platform Halcyon on its $44 million Series A funding round, plus its $6 million secured term loan. Partner Derek Colla led the Cooley team advising Halcyon.

Read more

Related contacts

Derek Colla
Partner, Miami
Jon Gavenman
Partner, Palo Alto
Wesley Dietrich
Associate, Washington, DC
Rasha Printz
Associate, Reston
Carley Cruea
Associate, Washington, DC

Related Practices & Industries

Razor’s Edge Forms Three New National Security Platforms

January 24, 2023

Cooley advised Razor’s Edge, a fund focused on high-growth technology investments in the national security market, in connection with its formation of a new platform, BlackSea Technologies. BlackSea builds and delivers intelligence, surveillance and reconnaissance capabilities, as well as other mission-tailored platforms for surface, subsurface and airborne operations across the naval domain. Cooley advised Razor’s Edge and BlackSea on the acquisition of Maritime Applied Physics Corporation in Baltimore, Maryland, and other BlackSea follow-on acquisitions.

Cooley separately advised Razor’s Edge in forming its new platform, Black Signal Technologies, with the acquisition of Blue Ridge Envisioneering, a developer of signal processing and electronic warfare solutions for national security customers. Cooley represented Black Signal in its follow-on acquisition of Silver Palm Technologies, a wireless engineering company specializing in products that support radio frequency and microwave distribution, signal conditioning and signal processing. 

Cooley also advised Veros Technologies, a technology company supporting critical cybersecurity missions for national security customers, in an equity investment by Razor’s Edge, and subsequently represented Veros in its acquisition of Bonfire Technologies, an elite cyber solutions company supporting similar customers and missions.

Related contacts

Aaron Binstock
Partner, Washington, DC
Andrew Lustig
Partner, Reston
Matthew Schwee
Partner, Reston
Vicky Kandabarow
Associate, Washington, DC
Danielle Joe
Associate, Washington, DC
Quay Strozier
Associate, Washington, DC
Rasha Printz
Associate, Reston
Kevin Milgram
Associate, Reston
Alex Elmore
Associate, Reston

Related Practices & Industries

IonQ Agrees to SPAC Merger With dMY Technology Group III

March 19, 2021

Cooley advised IonQ, a quantum computing hardware and software company, on its merger agreement with special purpose acquisition company dMY Technology Group III. Resulting in $650 million in gross proceeds, including $350 million from a fully committed PIPE, the transaction will make IonQ the first publicly traded pure-play hardware and software company in the quantum computing space. Partners Adam Ruttenberg, John McKenna, David Silverman, Jaime Chase and Mike Lincoln led the Cooley team advising IonQ.

Read more

Related contacts

Adam Ruttenberg
Partner, Washington, DC
John McKenna
Partner, Palo Alto
David Silverman
Partner, New York
Jaime L. Chase
Partner, Washington, DC
Mike Lincoln
Vice Chair, Reston
Alex Weaver
Associate, Washington, DC
Charles York
Associate, New York
Rasha Printz
Associate, Reston
Randy Sabett
Special Counsel, Washington, DC
Tiana Demas
Partner
Eileen Marshall
Partner, Washington, DC
Rick Jantz
Associate, Los Angeles Santa Monica
Helenanne Connolly
Partner, Reston
Sharon Connaughton
Special Counsel, Washington, DC
Howard Morse
Partner, Washington, DC
David Walsh
Partner, Reston
Mary Maher Lewis
Special Counsel, Reston
Kevin King
Partner, Washington, DC
Sarah Oliai
Associate, Washington, DC
Dillon Martinson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Matthew D. Silverman
Special Counsel, San Diego

Related Practices & Industries

Nanobiotix – $113 Million IPO

December 10, 2020

Cooley advised the underwriters on Nanobiotix’s $113.3 million initial public offering of 8,395,000 ordinary shares (global offering) – including the offering of 6,540,000 American depositary shares, each representing one ordinary share, in the US (the US offering) and a concurrent offering of 1,855,000 ordinary shares in certain jurisdictions outside of the US to certain investors (the European offering) – which includes the full exercise of the underwriters’ option to purchase additional shares. Jefferies acted as global coordinator and joint book-running manager for the global offering; Evercore Group and UBS Securities acted as joint book-running managers for the US offering; and Gilbert Dupont acted as manager for the European offering. Nanobiotix, whose securities now trade on the Nasdaq Global Select Market under the symbol NBTX, also trades on the Euronext Paris Market under the symbol NANO. Nanobiotix is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancers. Partners Brian Leaf, Div Gupta and David Boles led the Cooley team.

 

Related contacts

Div Gupta
Partner, New York
David Boles
Partner, London
Courtney Thorne
Partner, Boston
Katie Kazem
Partner, Reston
William DuVal
Associate, Reston
Rasha Printz
Associate, Reston

Related Practices & Industries

View more